arrow
G

Giuseppe Saglio

University of Turin
H指数:101
被引数:5.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting Dihydroorotate Dehydrogenase (hDHODH) beyond the barrier: discovery of MEDS700 as blood-brain barrier permeable hDHODH inhibitor

靶向二氢乳清酸脱氢酶(hDHODH)突破屏障:发现MEDS700作为可透过血脑屏障的hDHODH抑制剂

2026-04-270
PRE
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results

伊马替尼治疗慢性粒细胞白血病两次尼洛替尼巩固治疗后的无治疗缓解: 3期ENESTPath结果

Leukemia
IF13.4
2026-01-190
PRE
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study
2026-01-110
OA
Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing

组学与人工智能整合,利用COSMIC特征和泛癌种精准药物重定位对 Blast crisis CML 进行分层。

2025-11-240
PRE
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较,包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study

在Nilotinib减量后的慢性期慢性髓性白血病中的无治疗缓解:DANTE研究的96周更新

2025-08-080
OAAI
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1-Positive and -Negative Myeloproliferative Neoplasms

最近的翻译和治疗进展对BCR临床过程的影响::ABL1-Positive和阴性骨髓增殖性肿瘤

2025-01-180
PRE
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study

Asciminib对伊马替尼的补充在ASC4MORE研究中显示持续的高治疗率和深度分子反应,并延长随访时间

2024-12-180
OAAI
Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

酪氨酸激酶抑制剂在慢性髓性白血病中的停药:意大利673例患者的观察性研究

BLOOD
IF23.1
2024-11-050
PRE
CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or < 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

慢性粒细胞白血病患者在12个月时未达到BCR::ABL1 ≤ 1%(主要分子缓解,MMR)或在24个月时未达到BCR::ABL1 < 0.1%,其生存率显著较差,但并非由于CML相关死亡:一项意大利真实世界观察性研究的数据

BLOOD
IF23.1
2024-11-050
PRE
Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50-60 Years: A Campus CML Study

基线特征、治疗选择及早期一线TKI永久停药在50-60岁新诊断慢性髓性白血病患者中的研究:一项Campus CML研究

BLOOD
IF23.1
2024-11-050
PRE
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
CANCER
IF5.1
2023-06-246
OAAI